Feedback
Settings

Settings

Goto Application

695,146 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 69,515
1.WO/2025/137872TERMINAL DEOXYRIBONUCLEOSIDE TRANSFERASE MUTANT, PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 03.07.2025
Int.Class C12N 9/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
12transferring phosphorus containing groups, e.g. kinases (2.7)
 Appl.No PCT/CN2023/142043 Applicant BGI CHANGZHOU Inventor YANG, Weikang
Disclosed are a terminal deoxyribonucleoside transferase mutant, a preparation method therefor and a use thereof. A wild-type terminal deoxyribonucleoside transferase is subjected to molecular modification, to improve modified nucleic acid monomer polymerization activity and modified nucleic acid monomer catalysis efficiency, and to realize efficient single-base addition efficiency. Multiple 3'-O-blocking modified dNTPs substrates can be added to a 3'-OH end of an oligonucleotide single chain without a template, so that a novel and effective tool enzyme can be provided for the enzymatic method from de novo synthesis of nucleic acid.
2.WO/2025/139807MONOCLONAL ANTIBODY AGAINST CAPSULAR POLYSACCHARIDE OF KLEBSIELLA PNEUMONIAE SEROTYPE K64, HYBRIDOMA CELL LINE THEREOF AND USE THEREOF
WO - 03.07.2025
Int.Class C07K 16/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
12against material from bacteria
 Appl.No PCT/CN2024/138668 Applicant SHANGHAI BOFAN BIOTHERAPEUTICS CO., LTD. Inventor HE, Ping
A monoclonal antibody against the capsular polysaccharide of Klebsiella pneumoniae serotype K64, a hybridoma cell line thereof and the use thereof. The sequence information of the monoclonal antibody against the capsular polysaccharide of Klebsiella pneumoniae serotype K64 is as set forth in SEQ NO: 1-SEQ NO: 56, and the accession numbers of the hybridoma cell lines are CCTCC: C2023365, CCTCC: C2023366, CCTCC: C2023367, CCTCC: C2024340, CCTCC: C2024341, CCTCC: C2024342 and CCTCC: C2024343, respectively. The provided monoclonal antibody against the capsular polysaccharide of Klebsiella pneumoniae can specifically bind to the capsular polysaccharide of Klebsiella pneumoniae, which is beneficial for the typing of Klebsiella pneumoniae in clinical practice. Both in vivo and in vitro animal experiments have demonstrated that the monoclonal antibody against the capsular polysaccharide of Klebsiella pneumoniae has excellent effects in preventing and treating infections caused by Klebsiella pneumoniae serotype K64, which provides a way to solve the problems of Klebsiella pneumoniae infections and multi-drug resistance, has significant significance in the prevention, diagnosis and treatment of Klebsiella pneumoniae infections, and has an important value for the development of new-generation drugs against Klebsiella pneumoniae.
3.WO/2025/140077COMBINATION FOR DETECTING TARGET GENES AND USE THEREOF
WO - 03.07.2025
Int.Class C12Q 1/689
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
689for bacteria
 Appl.No PCT/CN2024/141311 Applicant SUZHOU PRECIGENOME LTD, CO; Inventor ZHANG, Xuan
Provided is a combination for specifically detecting P target genes. The combination comprises P pairs of primers used for amplifying P genes and P probes used for hybridizing the P genes. The P probes are respectively labelled with M different fluorescent groups having N concentrations; the types or concentrations of fluorescent groups carried by each probe among the P probes are different; and the P target genes and the fluorescent groups meet the following formula: 2≤P≤(MN+M)-X, M being a positive integer greater than or equal to 2, N ranging from 1 to 3, and X ranging from 0 to 19.
4.WO/2025/140227MODIFIED AMINOACYL-TRNA SYNTHETASE, NUCLEIC ACID CONSTRUCT AND GENETICALLY ENGINEERED STRAIN
WO - 03.07.2025
Int.Class C12N 9/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
 Appl.No PCT/CN2024/142051 Applicant KANGMA-HEALTHCODE (SHANGHAI) BIOTECH CO., LTD Inventor GUO, Min
Provided are a modified aminoacyl-tRNA synthetase, a nucleic acid construct and a genetically engineered strain. The provided recombinant aminoacyl-tRNA synthetase can significantly improve the introduction efficiency of non-natural amino acids in IVTT regardless of exogenous addition or integration into cells.
5.WO/2025/140482POLYNUCLEOTIDE CONSTRUCT CAPABLE OF IMPROVING EXPRESSION EFFECT OF TARGET POLYPEPTIDE AND USE THEREOF
WO - 03.07.2025
Int.Class C12N 15/80
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
80for fungi
 Appl.No PCT/CN2024/142987 Applicant NANJING BESTZYME BIO-ENGINEERING CO., LTD Inventor ZHANG, Guoxiu
A polynucleotide construct capable of improving the expression effect of a target polypeptide and the use thereof. The polynucleotide construct comprises a first polynucleotide encoding a selective marker, and one or more second polynucleotides encoding the target polypeptide; wherein the selective marker is selected from key enzymes associated with the survival of a host cell. Compared to a selective marker encoded by a wild-type encoding gene, the selective marker encoded by the first polynucleotide has a lower expression level and/or a lower enzyme activity. By means of reducing the expression level and/or enzyme activity of the selective marker in the polynucleotide construct, a host cell comprising high copy number of the target polypeptides can be efficiently screened out in a low-cost manner, and the yield and enzyme activity of the target polypeptide can be significantly increased, which has great guiding significance in the industrial production process of proteins.
6.WO/2025/140497PVRIG BINDING PROTEIN, BISPECIFIC ANTIBODY, AND USE
WO - 03.07.2025
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CN2024/143026 Applicant BIO-THERA SOLUTIONS, LTD. Inventor LIANG, Shizhong
Provided are a PVRIG binding protein, a bispecific antibody, and a use. The bispecific antibody or antigen-binding fragment comprises a first antigen-binding moiety capable of binding to PVRIG and/or a second antigen-binding moiety capable of binding to TIGIT. The PVRIG binding protein or bispecific antibody can be used for treating or preventing diseases.
7.WO/2025/140662ANTI-EGFR/HER3 ANTIBODIES AND USES THEREOF
WO - 03.07.2025
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CN2024/143476 Applicant BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Inventor LI, Zhuolin
Provided are anti-EGFR/HER3 antibodies, and antibody drug conjugates derived therefrom, and the use thereof.
8.WO/2025/141142A NOVEL METHOD FOR RECOVERING LIMONOID COMPOUNDS
WO - 03.07.2025
Int.Class C12P 17/18
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
17Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms
18containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
 Appl.No PCT/EP2024/088540 Applicant DICOT PHARMA AB Inventor SLAZAK, Blazej
The present invention relates to a novel method for obtaining the limonoid compounds of Formula IIa or IIb, and/or one or more esters and/or derivatives thereof, by culturing plant cells in a cell culture and recovering said compounds from said cells and/or cell culture. In one embodiment of the method the plant cells are obtained or originate from an explant/s of the corresponding plant. The present invention also relates to cell products of the method and the use of said products and compounds.
9.WO/2025/143482COMPOSITION FOR INDUCING DENDRITIC CELL DIFFERENTIATION, COMPRISING METAL-ORGANIC FRAMEWORK, AND USE THEREOF
WO - 03.07.2025
Int.Class C12N 5/0784
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0784Dendritic cells; Progenitors thereof
 Appl.No PCT/KR2024/016228 Applicant MEDIARK INC. Inventor KIM, Se Na
The present invention relates to a composition for inducing dendritic cell differentiation, comprising a metal-organic framework, and a use thereof, the composition having the effect of not only enabling the increasing of the expression of surface protein markers of dendritic cells, but also enabling the inducing of differentiation into dendritic cells having enhanced viability and migration properties when administered into an individual.
10.WO/2025/144082USH2A MINIPROTEIN FOR GENE THERAPY OF USHER SYNDROME TYPE II
WO - 03.07.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No PCT/RU2024/050227 Applicant RETINAFUND Inventor MALOGOLOVKIN, Aleksandr Sergeevich
The present invention relates to the field of biotechnology, namely to the USH2A miniprotein which, due to a small size enabling its delivery in viral vectors, retains LamGL, LamNT, EGF Lam, FN3 domains and PDZ-binding motif of a full-length protein, which are required for the USH2A protein function. Also disclosed is a nucleic acid encoding the USH2A miniprotein, an expression vector, and the use of said vector in the gene therapy of Usher syndrome type II. The invention can be effectively used for stable and high expression of the USH2A miniprotein.
# -